Bruno Salaun, PhD

Senior Scientist
GSK, Belgium

Disclosure(s): GlaxoSmithKline Biologicals SA: Employee, Stocks/Bonds

Poster(s):

• 96 - A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination
  Thursday, October 20, 2022

  12:15 PM – 1:30 PM US ET